MedTrace Logo

Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients

NCT01736657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2014-07-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the performance of the Spectra Optia system red blood cell exchange (RBCx) protocols (exchange and depletion/exchange) in study participants with sickle cell disease.

Conditions

Interventions

DEVICE

Red blood cell exchange in sickle cell

One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient

Sponsors & Collaborators

  • Terumo BCT

    lead INDUSTRY

Principal Investigators

  • Keith Quirolo, MD · Children's Hospital and Research Center at Oakland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736657 on ClinicalTrials.gov